News & Insights
Stay Informed With Our Latest Updates
Explore our comprehensive collection of news and in-depth insights spanning practice areas, industries, and regions.
Firm News February 17, 2026
Gibson Dunn Advised Galecto on Public Offering of Common Stock
Gibson Dunn advised Galecto, Inc. on its public offering of common stock, which generated aggregate gross proceeds to the company of approximately $316 million.
Firm News November 17, 2025
Gibson Dunn Represented Cogent Biosciences in Concurrent Public Offerings of Common Stock and Convertible Notes with Aggregate Gross Proceeds of $575 Million
Gibson Dunn represented Cogent Biosciences, Inc., a clinical-stage biotechnology company, in concurrent public offerings of common stock and convertible notes expected to result in aggregate gross proceeds of $575 million to Cogent
Firm News November 12, 2025
Gibson Dunn Advising Damora Therapeutics on Sale to Galecto and on $285 Million Private Placement by Galecto
Gibson Dunn is advising privately held biotechnology company Damora Therapeutics, Inc. on its sale to Galecto, Inc.
Firm News September 12, 2025
Gibson Dunn Advised Dianthus Therapeutics on $288 Million Offering of Common Stock and Pre-Funded Warrants
Gibson Dunn advised Dianthus Therapeutics, Inc., a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, on its $288 million offering of common stock and pre-funded warrants.
Firm News July 14, 2025
Gibson Dunn Represented The Williams Companies in $1.5 Billion Public Offering of Senior Notes
Gibson Dunn represented The Williams Companies, Inc. in a public offering of $750 million aggregate principal amount of 4.625% Senior Notes due 2030 and $750 million aggregate principal amount of 5.300% Senior Notes due 2035